While the pharmaceutical industry can play an important role in
converting the knowledge generated by the Human Genome Project into new
medicines, it also faces a popular perception that it is simply out to
make money by promoting unsafe medicines to an unsuspecting public.
Devalued
and Distrusted: Can the Pharmaceutical Industry Restore Its Broken Image?
offers a balanced view of the role of drug discovery in improving public
health.
The author, former Pfizer president John LaMattina addresses the
progress that industry has made in improving its abilities to measure
both risk and benefits of its new medicines, and then tackles the issue
of R&D productivity -- the reasons for the drop-off, and how the
industry can rehabilitate its image.
Devalued and Distrusted is intended to provide patients,
physicians, regulators, and payers with an appreciation of these issues
as well as the value that pharmaceutical R&D adds to society.
